Ep39: Julia Owens

Episode Summary

Executive Summary: Julia Owens, CEO of Melendo Therapeutics, shares her path from Ann Arbor to Berkeley/UCSF to biotech leadership, shaped by her father’s death from glioblastoma. She recounts multiple company pivots—from cancer to endocrine disorders to Prader-Willi syndrome—highlighting resilience, disciplined business development, and the importance of diverse leadership as Melendo advances a pivotal Prader-Willi trial.

Main Topics: Personal origin story and motivation (Priority: 5/5): Owens describes growing up in Ann Arbor, her mother’s influence, and her father’s early death from glioblastoma as the formative event that drove her toward medicine, science, and patient impact. Education and entry into biotech (Priority: 5/5): Her Berkeley and UCSF training, early exposure to Carolyn Bertozzi, and realization that she preferred broader science-business roles over academic bench research led her toward tech transfer and company-building. Career path through biotech business development (Priority: 4/5): Owens details roles at UCSF tech transfer, Tularik, Quatrix, and Lycera, emphasizing how each role expanded her understanding of deals, drug development, and the science-business interface. Founding and early failure of Aterocor/Melendo (Priority: 5/5): The company began with an adrenal cancer program, but inadequate human exposure and lack of efficacy forced a difficult shutdown and strategic pivot after a series of setbacks. Pivot to endocrine disease and PCOS (Priority: 5/5): Melendo shifted to rare endocrine disorders, including congenital adrenal hyperplasia and PCOS, backed by a major Series B and an AstraZeneca-licensed compound, but later encountered liver toxicity that ended that program. Acquisition of Prader-Willi asset and current strategy (Priority: 5/5): The company acquired lavoltidide from a small French firm and moved into Prader-Willi syndrome, leveraging existing endocrine expertise and a well-defined regulatory path, with a pivotal Phase 2 study supporting a planned registrational trial. Women in biotech leadership and board diversity (Priority: 4/5): Owens discusses being a female CEO in a male-dominated industry, the need for resilience, and the benefits of diverse boards; she notes Melendo’s board is 50% women.

Key Arguments: Owens’ father’s death from glioblastoma was the key personal driver behind her commitment to drug development and patient-focused work. Her career trajectory shows that biotech leadership can emerge from a business-science interface rather than a traditional academic path. Scientific rigor, networked relationships, and willingness to pivot are essential survival skills in startup biotech. A company can recover from program failure if it preserves capital, reassesses its assets, and acts quickly on new opportunities. Rare endocrine diseases can offer clear development paths when the biology, patient community, and regulatory strategy are well defined. Prader-Willi syndrome is a compelling target because of high unmet need, activated patient/regulatory precedent, and early evidence of meaningful activity. Diversity on leadership teams and boards improves dialogue and outcomes, even if the industry still underrepresents women in top roles.

Data Points: Kilimanjaro climb team size: 28 biotech executives and investors - Owens is joining Luke Timmerman’s cancer fundraising climb team Individual fundraising goal: $50,000 - Owens’ commitment to raise funds for Fred Hutch cancer research Mountain elevation: 19,000 feet - Highest peak in Africa, as described in the climb campaign Cancer research fundraising goal: $1 million - Team’s broader mission for Fred Hutch Company founding year: January 2012 - Melendo/Aterocor was founded around this time Series A financing: $15 million - Raised after initial seed support to advance adrenal cancer program Initial seed financing: $500,000 - State of Michigan match plus Fraser funding Series B financing: $62 million - Raised after pivot toward endocrine diseases and a broader pipeline Combined public financing in reverse merger: $85 million - Includes $35 million cash from OvaScience plus $30 million from existing investors and $20 million from new investors Clinical study size for adrenal cancer program: 60+ patients - 14-cohort dose escalation study in ultra-rare adrenal cancer Phase 2 Prader-Willi study size: 47 patients - Large double-blind randomized placebo-controlled study of lavoltidide Prader-Willi pivotal study size: 150 patients - Planned three-arm double-blind randomized placebo-controlled trial at 35 sites Prader-Willi site count: 35 centers - Planned pivotal study in the U.S. and Europe PCOS population estimate: 6 to 10 million women in the U.S. - Used to illustrate the size of the unmet need

Pivotal Quotes: "I was terrified, but incredibly excited about this and being part of such a great group of executives and doing this towards such an important mission towards trying to cure cancer." — Julia Owens: On joining the Kilimanjaro climb to fight cancer "I had lost my dad to cancer at a young age... I just had this sweet spot. I had to step in and see if we couldn't raise money and do something with this interesting product." — Julia Owens: Explaining why she became CEO of the then-new company focused on adrenal cancer "When you have a diverse set of perspectives in the room, higher quality dialogue and better outcomes result." — Julia Owens: Discussing the value of board diversity and women in biotech leadership

Implications: Melendo’s story shows how biotech companies survive by pivoting quickly, preserving scientific assets, and matching them to the right diseases and regulatory paths. It also underscores the value of diversity and persistence in building durable biotech organizations.